During the corresponding time, Immunocore Holdings Plc recorded a revenue increase by 18.34 % year on year, sequentially revenue grew by 8.67 %. While revenue at the Immunocore Holdings Plc's corporate clients
Immunocore Holdings Plc's Comment on Sales, Marketing and Customers
The company generates revenue from sales of therapies primarily in the United States, Europe, and international markets. Medison serves as the exclusive distribution partner for KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, South and Central America, and the Caribbean. In 2025, the company entered into a distribution and commercialization agreement with Er-Kim for KIMMTRAK in Turkey, the Middle East, North Africa, the Caucasus, and the Commonwealth of Independent States regions. Sales are influenced by coverage and reimbursement from third-party payors, including government health programs, commercial insurers, and managed healthcare organizations. Pricing and reimbursement agreements are in place in more than 20 European and other territories, including Germany, France, and Italy. The company outsources manufacturing to contract manufacturing organizations and does not own manufacturing facilities.
Immunocore Holdings Plc’s Comment on Sales, Marketing and Customers
The company generates revenue from sales of therapies primarily in the United States, Europe, and international markets. Medison serves as the exclusive distribution partner for KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, South and Central America, and the Caribbean. In 2025, the company entered into a distribution and commercialization agreement with Er-Kim for KIMMTRAK in Turkey, the Middle East, North Africa, the Caucasus, and the Commonwealth of Independent States regions. Sales are influenced by coverage and reimbursement from third-party payors, including government health programs, commercial insurers, and managed healthcare organizations. Pricing and reimbursement agreements are in place in more than 20 European and other territories, including Germany, France, and Italy. The company outsources manufacturing to contract manufacturing organizations and does not own manufacturing facilities.
Sources:
Immunocore Holdings Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Immunocore Holdings Plc’s corporate clients.
For your research, we’ve provided 9 tables on Immunocore Holdings Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
18.2 %